openPR Logo
Press release

Rheumatoid Arthritis Therapeutics Market to touch an aggregate of to $9.7 billion by 2023 growing at a CAGR of 8.2%

05-10-2018 12:11 PM CET | Health & Medicine

Press release from: HTF Market Intelligence Consulting Private Limited

Rheumatoid Arthritis Therapeutics Market to touch an aggregate

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects joints. It is characterized by synovial inflammation and gradual bone erosion over many years, and disease progression results in stiffness and pain, especially in the hands and feet, which hinders patient mobility. Without treatment, the disease leads to joint destruction and disability.

Request Brochure of the Report: https://www.htfmarketreport.com/sample-report/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market

Sustained Growth in Rheumatoid Arthritis Therapeutics Market over Forecast Period

Advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the RA market tremendously over the last two decades. Growth is expected to continue at a moderate pace from $5.6 billion in 2016 to $9.7 billion in 2023 at a compound annual growth rate (CAGR) of 8.2% in the Asia-Pacific (APAC) markets of India, Australia, China, South Korea and Japan. Japan accounted for the majority of the market in 2016 with a 65.4% share, followed by China, Australia, India and South Korea with 12.7%, 8.6%, 8.1% and 5.2% respectively.

Recently approved therapies anticipated to have a high impact include Eli Lilly and Incyte’s baricitinib and Sanofi and Regeneron’s sarilumab. Along with recently approved therapies, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Johnson & Johnson (J&J) and GlaxoSmithKline (GSK)’s sirukumab, and Galapagos’s filgotinib. Galapagos entered into a global collaboration agreement with Gilead in 2015 to develop and commercialize filgotinib for the treatment of inflammatory indications.

The treatment population is set to grow in the five APAC territories, which is a key driver for growth in market size. The loss of the patent exclusivity of major second-line biologic anti-tumor necrosis factor (TNF) therapies such as Orencia, Humira, and Simponi in the forecast period is not expected to reduce the market size due to slow generic erosion. However, this presents a major barrier to growth in market size, which is anticipated to be modest in spite of the entry of promising pipeline candidates.

Enquire Here For Free Consulting @: https://www.htfmarketreport.com/enquiry-before-buy/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market

Scope of the Report

- The current Asia-Pacific RA market contains novel products, including sirukumab, an anti-IL-6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an anti-IL-6 humanized IgG4 mAb; and RCT-18, a recombinant human B-lymphocyte stimulating factor (BLyS) receptor-antibody fusion protein.

- What are the competitive advantages of the existing novel drugs

- There are over 480 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

- Which classes of novel drugs are most prominent in the pipeline

- What is the potential for pipeline products to address unmet needs in the RA market

- Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

- How do failure rates vary by stage of development, molecule type, and molecular target

- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development

- Over the 2016-2023 forecast period, the Asia-Pacific RA therapeutics market is expected to increase in value at a compound annual growth rate of 8.2%, from $5.6 billion to over $9.7 billion.

- Which markets make the most significant contribution to the current market size

- What are the epidemiology trends in these markets

- Will new market entrants lead to substantial changes in annual therapy costs

- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets

- A rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs

- Licensing deals are the most common form of strategic alliance in the RA therapeutics market, with deal values ranging from under $10m to over $1 billion.

- How do deal frequency and value compare between target families and molecule types

- What were the terms and conditions of key licensing deals

Avail Discount on this 105 pages report @ https://www.htfmarketreport.com/request-discount/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market
Reasons to buy

- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and biologic registries.

- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.

- Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.

- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia, Japan and South Korea.

- Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com
Connect with us at
https://www.linkedin.com/company/13388569/
https://plus.google.com/u/0/+Htfmarketreportinsights
https://www.facebook.com/htfmarketintelligence
https://twitter.com/htfmarketreport

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatoid Arthritis Therapeutics Market to touch an aggregate of to $9.7 billion by 2023 growing at a CAGR of 8.2% here

News-ID: 1045821 • Views:

More Releases from HTF Market Intelligence Consulting Private Limited

Home And Laundry Care Market is Booming Worldwide | Procter & Gamble (P&G), Henkel, Unilever, Colgate-Palmolive
Home And Laundry Care Market is Booming Worldwide | Procter & Gamble (P&G), Henk …
According to HTF MI Latest Report, "Global Home And Laundry Care Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2030", the global Home And Laundry Care market size is expected to reach USD 188.7 Billion in 2024, that the market will reach USD 316.9 Billion by 2030, at a growth rate (CAGR) of 6.7% over the period 2024-2030. The Global Home And Laundry Care Market report from HTF MI is
Bio Polymer Market Growing High for Next Decade Return: BASF SE, Dow, Metabolix, BioAmber
Bio Polymer Market Growing High for Next Decade Return: BASF SE, Dow, Metabolix, …
According to HTF MI Latest Report, "Global Bio Polymer Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2030", the global Bio Polymer market size is expected to reach USD 19.37 Billion in 2024, that the market will reach USD 38.69 Billion by 2030, at a growth rate (CAGR) of 10.4% over the period 2024-2030. The Global Bio Polymer Market report from HTF MI is the single authoritative source of intelligence
Poly Aluminium Chloride Market is Going to Boom | SNF Floerger, LafargeHolcim, Kemira, Trojan Technologies
Poly Aluminium Chloride Market is Going to Boom | SNF Floerger, LafargeHolcim, K …
According to HTF MI Latest Report, "Global Poly Aluminium Chloride Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2030", the global Poly Aluminium Chloride market size is expected to reach USD 2.1 Billion in 2024, that the market will reach USD 3.5 Billion by 2030, at a growth rate (CAGR) of 6.5% over the period 2024-2030. The Global Poly Aluminium Chloride Market report from HTF MI is the single authoritative
Organic Bread Flour Market to Witness Massive Growth from 2024 to 2030 | General Mills, Grain Craft, Goodman Fielder, Heartland Mill
Organic Bread Flour Market to Witness Massive Growth from 2024 to 2030 | General …
The latest research study released by HTF MI "Global Organic Bread Flour Market" with 120+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know-how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint, and status. Understanding the segments helps in identifying the importance of different factors that aid market growth. Key Players in This Report Include: Associated British Foods plc (United Kingdom),

All 5 Releases


More Releases for Rheumatoid

How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis - New findings support research-based kit for management of Rheumatoid Arthritis Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively. Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data
Major Advancements| Competitor Landscape: Rheumatoid Arthritis
Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports. Competitor Landscape: Rheumatoid Arthritis Summary Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher - - Executive Summary: Contains analysis of key market events that have occurred during
Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the